左炔诺孕酮宫内节育器维持治疗改善非典型增生和早期子宫内膜癌保育治疗后的无病生存
该前瞻性研究纳入418例非典型增生(AEH)和早期子宫内膜癌(EC)患者,比较不同激素治疗方案。AEH总完全缓解率96%,EC为88%。治疗后妊娠率42%,AEH复发率26%,EC复发率36%。治疗后分娩和左炔诺孕酮宫内节育器(LNG IUD)维持治疗与更优的无病生存相关。
要点
- LNG IUD方案在AEH和EC中完全缓解率优于含MPA方案。
- AEH复发率26%,EC复发率36%,提示仍需密切随访。
- 治疗后分娩和LNG IUD维持治疗可降低复发风险。
核心结论
- LNG IUD激素治疗AEH和早期EC优于含MPA方案,但仍存在较高复发风险。
- 治疗后妊娠率满意,更广泛使用辅助生殖技术(ART)可进一步提高妊娠率且安全。
- 初始诊断为AEH、治疗后分娩和LNG IUD维持治疗与复发率降低相关。
研究设计与样本
- 治疗方案包括LNG IUD、GnRH激动剂(aGnRH)或高剂量口服甲羟孕酮(MPA)单用及联合。
主要发现
- AEH总完全缓解率96%,EC为88%(P<0.001)。
- AEH各方案中,LNG IUD+2次诊刮、LNG IUD+aGnRH、LNG IUD+3次诊刮的完全缓解率分别为98%、95%、100%,均不劣于其他(P>0.05),仅单用MPA完全缓解率87%(P=0.009)。
- EC四种方案中,LNG IUD+aGnRH+3次诊刮优于其他方案(完全缓解率96%,P=0.026)。
- 339例中位随访33个月(范围3-136),68%(232例)尝试妊娠,其中38%(89例)使用ART,活产率42%(97例)。
- AEH组复发率26%(50/196),EC组36%(51/143)(P=0.05);治疗后分娩(HR=0.24)或LNG IUD维持(HR=0.18)与更优无病生存相关(P<0.001),ART使用不影响无病生存。
临床怎么用
- 对AEH和早期EC要求保留生育功能的患者,优先考虑以LNG IUD为基础的激素治疗方案。
- 治疗后应鼓励妊娠,必要时使用ART,并考虑LNG IUD维持治疗以降低复发风险。
局限性
- 非随机设计可能引入选择偏倚。
- 随访时间中位数33个月,长期结局需进一步验证。
- 部分方案样本量较小,比较效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objectives were to (1) compare different regimens of hormonal therapy (HT) in young women with atypical endometrial hyperplasia (AEH) and early endometrial cancer (EC), (2) assess reproductive and oncologic outcomes and (3) explore possible predictors of complete response (CR) and disease free survival (DFS). METHODS: Reproductive age women with AEH and Grade 1-2 endometrioid EC with no or minimal myometrial invasion on MRI treated with different regimens of HT were prospectively analyzed. Treatment protocols included levonorgestrel intrauterine device (LNG IUD), gonadotropin-releasing hormone agonist (aGnRH) or high-dose oral medroxyprogesteron acetate (MPA) separately and in combinations. RESULTS: Total of 418 patients with AEH (n = 228) and EC (n = 190) aged 19-46 years received HT. Overall CR rate was 96% in AEH and 88% in EC patients (р < 0.001). None of the regimens used in AEH (LNG IUD + 2 D&C vs. LNG IUD + aGnRH vs. LNG IUD + 3 D&C) was found inferior to the others (CR of 98%, 95%, 100%, respectively, p > 0.05) except for MPA alone (CR 87%, р = 0.009). Out of four HT regimens used in EC LNG IUD + aGnRH+3 D&C was superior to all others (CR 96%, р = 0.026) where 2 D&Cs were performed or oral MPA was prescribed. The median follow-up for 339 patients was 33 months (range: 3-136), 68% of patients (n = 232) attempted conception, 38% (n = 89) of them used ART. The birth rate was 42% (n = 97). The rate of recurrence was 26% (50/196) in AEH group and 36% (51/143) in EC group (p = 0.05). Birth after treatment (HR = 0.24) or LNG IUD maintenance (HR = 0.18) were associated with superior DFS (p < 0.001 for both). ART use did not influence DFS. CONCLUSION: Hormonal therapy of AEH and early EC with LNG IUD is superior to MPA-containing regimens, however still carries high risk of recurrence. Post-treatment pregnancy rates are satisfactory and can be further improved by broader ART use which was proven safe. Initial diagnosis of AEH, post-treatment child birth and LNG IUD maintenance were associated with decreased rates of recurrence.
引用
- Novikova OV, Nosov VB, Panov VA, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecol Oncol. 2021. PMID: 33461741. doi:10.1016/j.ygyno.2021.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。